Sterile Injectable Contract Manufacturing Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Sterile Injectable Contract Manufacturing Market: By Product Type (Small Volume Products, Large Volume Products, Suspensions, Lyophilized Products, Others), By Service Type (Formulation, Analytical Services, Packaging, Others), By Drug Type (Cytokines, Monoclonal Antibodies, Vaccines, Insulin, Peptide Hormones, Antibiotics, Others), By Therapeutic Area (Diabetes, Cancer, Infectious Diseases, Neurological Diseases, Cardiovascular Diseases, Musculoskeletal Diseases, Others) and Region

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global Sterile Injectable Contract Manufacturing Market is expected to grow at a CAGR of xx% during the forecast period 2022 to 2028. Sterile injectable Contract Manufacturing Market are liquid dosage forms administered by parenteral route. These drugs directly enter into the circulation system and show quicker therapeutic action. Many pharmaceutical companies are outsourcing manufacturing due to lack of manufacturing capacities or to reduce the cost of manufacturing process. Contract manufacturers provide a wide range of services such as process optimization, analytical characterization, and cGMP among others. As chronic illness rates rise, technology advances, self-injecting parenteral device use rises, and supportive government rules stimulate growth in the prefilled syringe business, demand for prefilled syringes is on the rise (especially needlestick legislations). Because of the growing number of biologics and biosimilars, prefilled syringes are gaining favour among patients, healthcare providers, and the pharmaceutical industry as a whole. The pandemic is expected to have an impact on drug production and supply chains, which will have a short-term impact on the prefilled syringes business. Healthcare providers (HCPs) must integrate virtual healthcare and digital technology in order to maintain their regular visits, and HCPs have adapted to new means of giving treatment via telemedicine. Apps could also aid in the self-management of chronic disorders like diabetes, which benefits from continuous glucose monitoring. Contract manufacturing organisations (CMOs) can improve their core skills and position themselves as one-stop shops for a specific dosage form by broadening their service offerings. Horizontal integration, on the other hand, is more costly and risky because the CMO must begin from the ground up. This approach, which also complies with the bulk of legal requirements, allows current clients to cross-sell new services. CMOs looking to expand their business have two alternatives, both vertically and horizontally: they can either give additional services for current dosage forms or API manufacturing, or they can offer the same services for new dosage forms. Vertical integration is easier in some cases, but horizontal integration reduces a CMO’s reliance on a single dosage form.

Sterile Injectable Contract Manufacturing Market

MARKET SUMMARY
-
x% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– x%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Sterile Injectable Contract Manufacturing Market

  • The report on global Sterile Injectable Contract Manufacturing Market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, service type, drug type, therapeutic area and geography.
  • Sterile Injectable Contract Manufacturing Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa
Key Players
  • Baxter International, Inc. (U.S.)
  • Bryllon LLC (U.S.)
  • Pfizer CentreOne (Pfizer, Inc.) (U.S.)
  • Aenova Holding GmbH (Germany)
  • Vetter Pharma-Fertigung GmbH & Co. KG (Germany)
Dynamics

Sterile Injectable Contract Manufacturing Market

Increase in the prevalence of chronic diseases such as cancer, diabetes, and immunological disorders, development of newer vaccines, patent expiries of blockbuster drugs, and increase in the focus on reformulation of existing products are anticipated to fuel the sterile injectable contract manufacturing market. Moreover, growing demand for sterile injectable products and dearth of captive sterile injectable manufacturing facilities are expected to propel the market over forecast period. However, stringent regulatory guidelines for the manufacturing and higher manufacturing cost may restrain the growth of sterile injectable contract manufacturing market over the forecast period.


North-America got significant share

Sterile Injectable Contract Manufacturing Market

Geographically, sterile injectable contract manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa regions. North America sterile injectable contract manufacturing market expected to exhibit significant growth owing to increase in the number of pharmaceutical companies minimal manufacturing facilities, rise in demand for injectable products due to rise in prevalence of chronic diseases such as cancer, and rise in number of contract manufacturing organizations are propel the market. Europe sterile injectable contract manufacturing market is driven by increase in the prevalence of chronic diseases, patent expiries of blockbuster drugs, rise in R&D for reformulation of existed drugs are boost the market. Asia Pacific sterile injectable contract manufacturing market expected to present lucrative growth opportunities due to presence of large patient pool, low manufacturing cost in Asia Pacific region, and rise in focus on R&D for the innovation of newer drugs are fuel the market.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market and Forecast
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Sterile Injectable Contract Manufacturing Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Baxter International, Inc. (U.S.)
  • Bryllon LLC (U.S.)
  • Pfizer CentreOne (Pfizer, Inc.) (U.S.)
  • Aenova Holding GmbH (Germany)
  • Vetter Pharma-Fertigung GmbH & Co. KG (Germany)
  • Catalent Pharma Solutions (Catalent, Inc.) (U.S.)
  • West Pharmaceutical Services, Inc. (U.S.)
  • AbbVie, Inc. (U.S.)
  • Jubilant HollisterStier LLC (Jubilant Life sciences) (India)
  • Recipharm AB (Sweden)

Description

The global Sterile Injectable Contract Manufacturing Market is expected to grow at a CAGR of xx% during the forecast period 2022 to 2028. Sterile injectable Contract Manufacturing Market are liquid dosage forms administered by parenteral route. These drugs directly enter into the circulation system and show quicker therapeutic action. Many pharmaceutical companies are outsourcing manufacturing due to lack of manufacturing capacities or to reduce the cost of manufacturing process. Contract manufacturers provide a wide range of services such as process optimization, analytical characterization, and cGMP among others. As chronic illness rates rise, technology advances, self-injecting parenteral device use rises, and supportive government rules stimulate growth in the prefilled syringe business, demand for prefilled syringes is on the rise (especially needlestick legislations). Because of the growing number of biologics and biosimilars, prefilled syringes are gaining favour among patients, healthcare providers, and the pharmaceutical industry as a whole. The pandemic is expected to have an impact on drug production and supply chains, which will have a short-term impact on the prefilled syringes business. Healthcare providers (HCPs) must integrate virtual healthcare and digital technology in order to maintain their regular visits, and HCPs have adapted to new means of giving treatment via telemedicine. Apps could also aid in the self-management of chronic disorders like diabetes, which benefits from continuous glucose monitoring. Contract manufacturing organisations (CMOs) can improve their core skills and position themselves as one-stop shops for a specific dosage form by broadening their service offerings. Horizontal integration, on the other hand, is more costly and risky because the CMO must begin from the ground up. This approach, which also complies with the bulk of legal requirements, allows current clients to cross-sell new services. CMOs looking to expand their business have two alternatives, both vertically and horizontally: they can either give additional services for current dosage forms or API manufacturing, or they can offer the same services for new dosage forms. Vertical integration is easier in some cases, but horizontal integration reduces a CMO’s reliance on a single dosage form.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX